# Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)

> **NCT04456088** · PHASE2 · WITHDRAWN · sponsor: **Beyond Air Inc.**

## Conditions studied

- COVID-19
- SARS-CoV 2
- Respiratory Disease
- Pneumonia, Viral
- Corona Virus Infection

## Interventions

- **COMBINATION_PRODUCT:** 150 ppm Nitric Oxide delivered through LungFit Delivery System
- **COMBINATION_PRODUCT:** 80 ppm Nitric Oxide delivered through LungFit Delivery System

## Key facts

- **NCT ID:** NCT04456088
- **Lead sponsor:** Beyond Air Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-15
- **Primary completion:** 2020-11-15
- **Final completion:** 2020-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Terminated (halted prematurely)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456088, "Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04456088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*